title: Patent litigation could make 2017 no 'dancing' matter.
abstract: No matter how you slice it, 2016 was a banner year for biosimilars. Still, the high-stakes marketing, regulatory, and legal combat between originators and biosimilars is a long way from over. So far, the originators have been able to hold their ground and thwart the launch of biosimilars with patent lawsuits.
authors.forename: Thomas
authors.initials: T
authors.lastname: Reinke
mesh_terms: D059451:Biosimilar Pharmaceuticals; D017277:Drug Approval; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D006801:Humans; D008389:Marketing of Health Services; D010330:Patents as Topic / Q000331:legislation & jurisprudence*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D059451:Biosimilar Pharmaceuticals